Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Quantitative and qualitative tools allow better understanding of mixing in a single-use bioprocessing system.

Evaluating Mixing in a Single-Use Bioprocessing System

Martin KÃ¶berle, PhD, is head of Analytical Development &Stability Testing, at Hermes Pharma.

Detlev Haack, PhD, is head of Research & Development at Hermes Pharma.

Hot-melt coating was used to develop taste-masked orally disintegrating granules of acetaminophen and caffeine.

From Bitter to Sweet: Developing a User-Friendly Painkiller

Takeda will invest more than 100 million Euros to build a new manufacturing plant for its dengue vaccine candidate in Singen, Germany.

Takeda Builds Dengue Vaccine Manufacturing Plant in Germany

Catalent adds two softgel facilities and packaging capabilities with acquisition of Canada-based Accucaps.

Catalent Expands Softgel Capacity with Accucaps Acquisition

Oxford Genetics has been awarded a grant to develop packaging cell lines for virus bioproduction and will work in collaboration with the University of Oxford to generate cell lines for the scalable manufacture of retrovirus and lentivirus vectors.

Oxford Genetics and University of Oxford Form Virus Production Pact

Avecia is adding drug substance capacity at its Milford, MA manufacturing site.

Nitto Avecia Expands Oligonucleotide Manufacturing Capacity

Research by agency scientists may help speed development of Zika virus vaccines.

FDA Researchers Develop Mouse Model for Zika Studies

Idifarma has announced a growth of more than 50% over the past two years. Revenue is expected to hit approximately EUR5.3 million in 2016, growing from EUR3.5 million in 2014.

Idifarma Reports Record Growth

German biotech ARTES and Iranian biopharma manufacturer BioSun will develop an HPV vaccine.

ARTES and BioSun Collaborate on HPV Vaccine

David W. Osborne, PhD, is Chief Scientific Officer and Founder, Independent Derm Solutions, LLC, 4215 Creekside Court, Fort Collins, CO 80525.

This article will clarify reasonable expectations for the responsibilities of topical product formulation developers and for excipient suppliers regarding the information and samples for experiments needed for QbD.